Dr. Saby George Dr. Saby George

Saby George

MD, FACP
Medical Oncology

Specializing In:

Kidney Cancer Prostate Cancer Bladder Cancer

Special Interests:

Kidney cancer: My interests include clinical trials, novel drug development, mechanism of resistance formation to tyrosine kinase inhibitors, improving the response evaluation criteria and development of biomarkers. Prostate cancer: Castrate refractory prostate cancer, high Gleason score disease, improving androgen deprivation therapy and biomarker development.

About Saby George

Positions

Roswell Park Comprehensive Cancer Center
  • Associate Professor of Oncology
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
  • Department of Medicine

Background

Education and Training:

  • Kottayam Medical College, Kerala, India

Residency:

  • Wright State University, Dayton, OH

Fellowship:

  • Experimental therapeutics-Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
  • Medical Oncology-University of Texas Health Sciences Center at San Antonio, San Antonio, TX

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Clinical Trials


Featured on Cancer Talk


Publications

Full Publications list on PubMed
  • Pokharel S, Dhillon SS, Ylagan L, George S, Yendamuri S. Sclerosing Pneumocytoma with Lymph Node Metastasis. J Thorac Oncol. 2016 Jun 23. pii: S1556-0864(16)30522-6. doi: 10.1016/j.jtho.2016.06.005. [Epub ahead of print] No abstract available. PMID: 27346414
  • George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016 May 12. doi: 10.1001/jamaoncol.2016.0775. [Epub ahead of print] PMID: 27243803
  • Pokuri VK, Sule N, Perfetto C, Duff M, Kopp C, Guru K, Shah D, George S. A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. J Community Support Oncol. 2016 Feb;14(2):72-5. doi: 10.12788/jcso.0218. PMID: 26955660
  • Gill S, Kauffman EC, Kandel S, George S, Schwaab T, Xu B. Incidence of Clear Cell Papillary Renal Cell Carcinoma in Low-Grade Renal Cell Carcinoma Cases: A 12-Year Retrospective Clinicopathologic Study From a Single Cancer Center. Int J Surg Pathol. 2016 May;24(3):207-12. doi: 10.1177/1066896915613432. Epub 2015 Oct 27. PMID: 26510859
  • Ammannagari N, Javvaji C, Danchaivijitr P, George S. Dramatic PSA Increase With Tumor Shrinkage After Initiating Degarelix in Advanced Prostate Cancer. Clin Genitourin Cancer. 2016 Feb;14(1):e123-5. doi: 10.1016/j.clgc.2015.09.012. Epub 2015 Oct 3. No abstract available. PMID: 26508365
  • Pokuri VK, Syed JR, Yang Z, Field EP, Cyriac S, Pili R, Levine EG, Azabdaftari G, Trump DL, Guru K, George S. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. Clin Genitourin Cancer. 2016 Feb;14(1):e59-65. doi: 10.1016/j.clgc.2015.09.013. Epub 2015 Oct 3. PMID: 26508364
  • Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. PMID: 26406148
  • Pokuri VK, Nourkeyhani H, Betsy B, Herbst L, Sikorski M, Spangenthal E, Fabiano A, George S. Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms. J Natl Compr Canc Netw. 2015 Jul;13(7):e49-55. PMID: 26150586
  • Sule N, Xu BO, El Zein D, Szigeti K, George S, Kane JM, Cheney R. Radiation-induced Chondrosarcoma of the Bladder. Case Report and Review of Literature. Anticancer Res. 2015 May;35(5):2857-60. PMID: 25964567
  • Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1. PMID: 25452452
  • Zhong H, George S, Kauffman E, Guru K, Azabdaftari G, Xu B. Clinicopathologic characterization of intradiverticular carcinoma of urinary bladder - a study of 22 cases from a single cancer center. Diagn Pathol. 2014 Nov 26;9:222. doi: 10.1186/s13000-014-0222-8. PMID: 25425482
  • Hanzly M, Aboumohamed A, Yarlagadda N, Creighton T, Digiorgio L, Fredrick A, Rao G, Mehedint D, George S, Attwood K, Kauffman E, Narashima D, Khushalani NI, Pili R, Schwaab T. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology. 2014 May;83(5):1129-34. doi: 10.1016/j.urology.2014.02.005. PMID: 24767525
  • Pokuri V, Sule N, Soofi Y, Xu B, Guru K, George S. A case of unusual mast cell response with interstitial cystitis-like symptoms to neoadjuvant chemotherapy for muscle-invasive transitional cell carcinoma of the bladder. J Natl Compr Canc Netw. 2013 Dec 1;11(12):1459-63. PMID: 24335680
  • Rehman S, Crane A, Din R, Raza SJ, Shi Y, Wilding G, Levine EG, George S, Pili R, Trump DL, Guru KA. Understanding avoidance, refusal, and abandonment of chemotherapy before and after cystectomy for bladder cancer. Urology. 2013 Dec;82(6):1370-5. doi: 10.1016/j.urology.2013.07.055. Epub 2013 Oct 11. PMID: 24125689
  • George S, Pili R. Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer. Curr Oncol Rep. 2013 Apr;15(2):65-8. doi: 10.1007/s11912-013-0295-7. Review. PMID: 23334511
  • George S, Pili R, Carducci MA, Kim JJ. Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw. 2011 Sep 1;9(9):1011-8. Review. PMID: 21917625
  • George S, Brenner A, Sarantopoulos J, Bukowski RM. RANK ligand: effects of inhibition. Curr Oncol Rep. 2010 Mar;12(2):80-6. doi: 10.1007/s11912-010-0088-1. Review. PMID: 20425591
  • George S, Shah SN, Bukowski RM. Stable disease in renal cell carcinoma after using signal transduction inhibitors. Rev Recent Clin Trials. 2010 May;5(2):117-22. Review. PMID: 20199387
  • George S, Bukowski RM. Role of everolimus in the treatment of renal cell carcinoma. Ther Clin Risk Manag. 2009 Oct;5(5):699-706. Epub 2009 Sep 15. PMID: 19774211
  • Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009 Jan 10;27(2):235-41. doi: 10.1200/JCO.2008.18.0000. Epub 2008 Dec 8. PMID: 19064974
  • George S, Dreicer R, Au JJ, Shen T, Rini BI, Roman S, Cooney MM, Mekhail T, Elson P, Wientjes GM, Ganapathi R, Bukowski RM. Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2008 Sep;6(2):79-85. doi: 10.3816/CGC.2008.n.012. PMID: 18824429
  • George S, Kasimis BS, Cogswell J, Schwarzenberger P, Shapiro GI, Fidias P, Bukowski RM. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer. Clin Lung Cancer. 2008 May;9(3):160-5. doi: 10.3816/CLC.2008.n.024. PMID: 18621626
  • George S, Bukowski RM. Biomarkers in clear cell renal cell carcinoma. Expert Rev Anticancer Ther. 2007 Dec;7(12):1737-47. Review. PMID: 18062748
  • George S, Hutson TE, Mekhail T, Wood L, Finke J, Elson P, Dreicer R, Bukowski RM. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Jul;62(2):347-54. Epub 2007 Oct 2. PMID: 17909807
  • George S, Rini BI. Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapies. Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S40-4. Review. PMID: 17239283

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment

See what others are saying about Saby George, MD, FACP, and leave your own review.

Leave a Review